CYRANO THERAPEUTICS
Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell. The company's product (CYR-001) repurposes an approved molecule (Theophylline) for this new indication and has been tested with success in a pilot study. Eight out of the 10 patients treated had significant improvement in taste and smell within 2 weeks with no reported side effects. The primary treatment provider will be the Otolaryngologist (Ear, Nose, and Throat specialist) and credible clinical investigators in this specialty have been identified and have expressed interest in participating in the clinical program. Cyrano Therapeutics was founded in 2014 and is headquartered in Washington, DC, USA.
CYRANO THERAPEUTICS
Social Links:
Industry:
Health Care Medical Medical Device Therapeutics
Founded:
2014-01-01
Address:
Washington, District Of Columbia, United States
Country:
United States
Website Url:
http://www.cyranotherapeutics.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
12.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default WordPress Apache Wordpress Plugins Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Interline Therapeutics
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
Remiges Ventures
Remiges Ventures investment in Series A - Cyrano Therapeutics
Lumira Ventures
Lumira Ventures investment in Series A - Cyrano Therapeutics
Official Site Inspections
http://www.cyranotherapeutics.com
- Host name: 244.0.153.160.host.secureserver.net
- IP address: 160.153.0.244
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Cyrano Therapeutics"
Smell Loss Therapy | Cyrano Therapeutics - The …
Olfactory dysfunction, or the loss or impairment of the sense of smell, affects millions worldwide. This condition, often caused by viral infections, head trauma, or neurodegenerative diseases, impacts more than just the ability to detect …See details»
Smell Therapy Research Contact – Reach Out for Information
[email protected] If you’re interested in learning more about the clinical trial and prefer to connect directly with a site near you, we have research locations across the country. …See details»
Cyrano Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Cyrano Therapeutics is developing an intranasal product designed to restore function in patients with a chronic loss of taste and smell. The …See details»
Smell Loss Therapy Research - Cyrano Therapeutics
Taka Koda is Partner at Remiges Ventures, a US-Japan venture capital firm focusing on therapeutics. With over 20 years of business development and venture investment experience, he founded and served in board capacities …See details»
Cyrano Therapeutics - LinkedIn
At Cyrano Therapeutics, we believe that the ability to smell and taste are more than just senses, they are integral to our well-being. Our team is dedicated to developing pharmaceutical and device ...See details»
Cyrano Therapeutics - Overview, News & Similar companies
Cyrano Therapeutics contact info: Phone number: (925) 822-6461 Website: www.cyranotherapeutics.com What does Cyrano Therapeutics do? Cyrano Therapeutics is a …See details»
Funding for Development of Treatment for Smell loss
Cyrano Therapeutics Secures $9.0 Million Series B Financing to Advance Clinical Development of CYR-064 for Treatment of Post-Viral Smell Loss.See details»
Cyrano to initiate Phase II trial of nasal spray therapy …
Jan 19, 2023 The trial is expected to enrol subjects at 20 US clinical sites and will assess the therapy for a period of six months. Cyrano Therapeutics CEO Rick Geoffrion said: “Clearance of the IND for CYR-064 brings us one step closer …See details»
Cyrano Therapeutics Announces FDA Clearance of IND …
Jan 18, 2023 Currently no FDA-approved therapy for this serious condition. Initiation of Phase 2 clinical trial expected to occur in Q2 2023. DELRAY BEACH, Fla., Jan. 18, 2023 /PRNewswire/ -- Cyrano ...See details»
Cyrano Therapeutics Announces FDA Clearance of IND Application …
Jan 18, 2023 Cyrano Therapeutics, a biopharmaceutical company developing medicines for patients with hyposmia (smell loss), announced today that the U.S. Food and Drug …See details»
Cyrano Therapeutics Secures $9.0 Million Series B …
Jan 16, 2024 To learn more, please visit cyranotherapeutics.com. About the FLAVOR Trial The Phase 2 FLAVOR trial is a 150 subject randomized, double-blinded, placebo-controlled, multi-dose, multi-site clinical ...See details»
Cyrano Therapeutics Enrolls First Patient in Phase 2 Trial of CYR …
Oct 12, 2023 For more information, please visit cyranotherapeutics.com. SOURCE Cyrano Therapeutics. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? …See details»
Investing in Regenerative Medicine - Cyrano Therapeutics
Explore the potential of investing in regenerative medicine with Cyrano Therapeutics, a leader in smell loss therapy innovation.See details»
CYR-064 - Drug Targets, Indications, Patents - Synapse - Patsnap
To learn more, please visit cyranotherapeutics.com. About the FLAVOR Trial The Phase 2 FLAVOR trial is a 150 subject randomized, double-blinded, placebo-controlled, multi-dose, …See details»
Cyrano Therapeutics Secures $9.0 Million Series B Financing to …
Jan 16, 2024 Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company. Since our foundation, we have been working diligently to develop …See details»
Cyrano Therapeutics Raises $12.8 Million to Complete Phase 2 …
WASHINGTON, Dec. 10, 2020 /PRNewswire/ -- Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy for smell and flavor …See details»
First Patient in Smell Loss; Cyrano Therapeutics begins Enrollment
Learn more about Cyrano Therapeutics' enrolling the first patient trial in smell loss — their first attempt of Phase 2 Trial called FLAVOR.See details»
Cyrano Therapeutics Enrolls First Patient in Phase 2 Trial
Oct 12, 2023 There is currently no FDA-approved therapy for this increasingly prevalent and serious chronic sensory condition. DELRAY BEACH, Fla., Oct. 12, 2023 /PRNewswire/ -- …See details»
CYR-064 - Drug Targets, Indications, Patents - Synapse
To learn more, please visit cyranotherapeutics.com. About the FLAVOR Trial The Phase 2 FLAVOR trial is a 150 subject randomized, double-blinded, placebo-controlled, multi-dose, …See details»
Cyrano Therapeutics Enrolls First Patient in Phase 2 Trial of CYR …
There is currently no FDA-approved therapy for this increasingly prevalent and serious chronic sensory condition Delray Beach, FL, October 12, 2023 – Cyrano Therapeutics, Inc., a …See details»